葵花药业：盐酸非索非那定口服混悬液获药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its subsidiary's drug, a hydrochloride formulation of fexofenadine oral suspension, which is now registered as a prescription medication [1] Group 1: Drug Approval Details - The drug is classified as a Class 3 chemical drug and is intended for the relief of seasonal allergic rhinitis symptoms in children aged 2 years and older, as well as chronic idiopathic urticaria skin symptoms in children aged 6 months and older [1] - The registered specification of the drug is 120ml containing 0.72g of the active ingredient [1]